BlackRock
ELVN icon

BlackRock’s Enliven Therapeutics ELVN Stock Holding History

BlackRock’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$221M Buy
4,359,704
+674,997
+18% +$28.7M ﹤0.01% 1731
2026
Q1 		$144M Buy
3,684,707
+71,381
+2% +$1.98M ﹤0.01% 1878
2025
Q4 		$55.6M Buy
3,613,326
+94,802
+3% +$1.89M ﹤0.01% 2454
2025
Q3 		$72M Buy
3,518,524
+551,390
+19% +$11.1M ﹤0.01% 2284
2025
Q2 		$59.5M Sell
2,967,134
-30,995
-1% -$587K ﹤0.01% 2350
2025
Q1 		$59M Buy
2,998,129
+33,001
+1% +$710K ﹤0.01% 2292
2024
Q4 		$66.7M Buy
2,965,128
+28,486
+1% +$738K ﹤0.01% 2293
2024
Q3 		$75M Buy
2,936,642
+205,869
+8% +$4.77M ﹤0.01% 2243
2024
Q2 		$63.8M Buy
2,730,773
+917,422
+51% +$19.3M ﹤0.01% 2278
2024
Q1 		$31.9M Sell
1,813,351
-36,307
-2% -$557K ﹤0.01% 2722
2023
Q4 		$25.6M Buy
1,849,658
+282,126
+18% +$3.45M ﹤0.01% 2866
2023
Q3 		$21.4M Buy
1,567,532
+21,057
+1% +$355K ﹤0.01% 2906
2023
Q2 		$31.6M Buy
1,546,475
+1,512,680
+4,476% +$30.6M ﹤0.01% 2757
2023
Q1 		$740K Buy
33,795
+5,157
+18% +$105K ﹤0.01% 4433
2022
Q4 		$469K Buy
28,638
+1,189
+4% +$19K ﹤0.01% 4621
2022
Q3 		$252K Sell
27,449
-3,291
-11% -$19.4K ﹤0.01% 4916
2022
Q2 		$150K Buy
30,740
+3,891
+14% +$19K ﹤0.01% 5113
2022
Q1 		$202K Buy
26,849
+900
+3% +$5.93K ﹤0.01% 5103
2021
Q4 		$234K Buy
25,949
+175
+0.7% +$2.29K ﹤0.01% 5075
2021
Q3 		$420K Buy
25,774
+6,355
+33% +$132K ﹤0.01% 4804
2021
Q2 		$613K Sell
19,419
-94,673
-83% -$2.94M ﹤0.01% 4646
2021
Q1 		$3.85M Buy
114,092
+3,134
+3% +$159K ﹤0.01% 4058
2020
Q4 		$9.79M Buy
110,958
+26,260
+31% +$2.2M ﹤0.01% 3372
2020
Q3 		$6.89M Sell
84,698
-1,039
-1% -$93.7K ﹤0.01% 3432
2020
Q2 		$9.48M Buy
+85,737
New +$9.59M ﹤0.01% 3210

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock's ELVN Position: Q2 2026 in Review

BlackRock increased its Enliven Therapeutics (ELVN) stake by 18% in Q2 2026, buying an estimated $28.7M and bringing the position to 4,359,704 shares worth $221M. The position accounts for ﹤0.01% of the portfolio, ranked #1731.

BlackRock first reported a position in ELVN in Q2 2020 and has held it in 25 quarters since. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • BlackRock held 4,359,704 shares of Enliven Therapeutics worth $221M as of Q2 2026.
  • BlackRock bought 674,997 Enliven Therapeutics shares in Q2 2026, an estimated $28.7M.
  • Enliven Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1731 holding.
  • BlackRock first reported a position in Enliven Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.